FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody or its antigen-binding fragment specifically binding to human sclerostin, a DNA molecule coding it, as well as to a vector and a host cell containing said DNA molecule. What is also disclosed is a pharmaceutical composition containing said antibody or its antigen-binding fragment. Invention also relates to use of said antibody or antigen-binding fragment thereof or pharmaceutical composition comprising it, for treating bone disease or human sclerostin mediated disorder (SOST), and for use in increasing at least one of the bone mass, bone mineral density, mineral bone content or bone strength.
EFFECT: invention enables effective treatment of a disease or disorder mediated by human sclerostin.
33 cl, 2 dwg, 11 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING ANTIBODY TO SOST, AND ITS USE | 2018 |
|
RU2779430C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| ANTIBODY AGAINST BETA-AMYLOID, ANTIGEN-BINDING FRAGMENT OF SAID ANTIBODY, AND APPLICATION THEREOF | 2019 |
|
RU2777844C1 |
| ANTIBODY BINDING HUMAN IL-4R, ANTIGEN-BINDING FRAGMENT THEREOF, AND MEDICAL APPLICATION THEREOF | 2019 |
|
RU2779649C1 |
| INTERLEUKIN 15 PROTEIN COMPLEX AND USE THEREOF | 2015 |
|
RU2711979C2 |
| ANTIBODY TO CD40, ITS ANTIGENE-BINDING FRAGMENT AND ITS MEDICAL USE | 2018 |
|
RU2779128C2 |
| ANTIBODY AGAINST B7-H3, ITS ANTIGEN-BINDING FRAGMENT AND THEIR MEDICAL USE | 2018 |
|
RU2765306C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| ANTIBODY TO TIGIT AND ITS USE | 2019 |
|
RU2786434C2 |
| BISPECIFIC PROTEIN | 2019 |
|
RU2784486C1 |
